DBVT DBV Technologies S.A.
USHealthcareAs of 2026-07-10 16:00
Why DBVT matters now
DBV Technologies S.A. (DBVT) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.49 with +2.55% on the session and $394.5M in market capitalization; recent performance reads 1-month -16.10% and YTD -18.99%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-47.6M, and EPS of $-0.55. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.7%.
The latest indexable market news headline is "Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $48.00; recent insider activity includes Lee Philina filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.69
P/S
0.00
EV/EBITDA
-2.06
DCF Value
$1.72
FCF Yield
-27.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-130.1%
ROA
-63.0%
ROIC
-74.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-47.6M | $-0.55 |
| Q4 2025 | $0.00 | $-44.8M | $-0.60 |
| FY 2025 | $0.00 | $-146.9M | $-1.70 |
| Q3 2025 | $0.00 | $-33.0M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$46.33
Target (Median)
$48.00
Target Range
$40.00 - $51.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
FR
Exchange
—
Beta
-0.22
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.